
    
      IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is
      to determine safety and evaluate PK, PD and clinical activity of IMC-001. Multiple dose
      levels of IMC-001 will be tested in subjects with metastatic or locally-advanced solid
      tumors. Data from this study will also help determine the recommended phase 2 dose of
      IMC-001.
    
  